Although HER2-targeted therapy has shown benefits in both early and advanced breast cancer regardless of hormone receptor status, it is becoming increasingly clear that hormone receptor expression is associated with trastuzumab resistance. This evidence concerns the gene ERBB2 and breast carcinoma.